Teradyne's robotics group cut about another 14% of its staff worldwide as revenue growth has not matched expectations.

The near-term outlook for ClearPoint's biopharma business is also now clouded by FDA uncertainty around uniQure's AMT-130.

Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization SOLANA BEACH, CA / ACCESS Newswire ...

What if you'd invested in Teradyne (TER) ten years ago? It may not have been easy to hold on to TER for all that time, but if you did, how much would your investment be worth toda ...

Caracol will use Formnext 2025 as a venue to demonstrate its new products: Eidos Manufacturing software suite and a 3D printed catamaran.

Johns Hopkins APL has installed a state-of-the-art robotic arm to advance repair and manufacturing for the maritime ...

One in four people suffers a stroke during their lifetime, according to the World Stroke Organisation. Stroke survivors with ...

CEO Francesco De Stefano on why he believes the U.S. is the place to go to define the future of industrial-scale 3D printing.